<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120965">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829971</url>
  </required_header>
  <id_info>
    <org_study_id>MRX34-101</org_study_id>
    <nct_id>NCT01829971</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension</brief_title>
  <official_title>A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirna Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mirna Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or
      those with liver metastasis from other cancers. The drug is given intravenously, twice per
      week for three weeks in a row and then one week off. Additionally patients with hematologic
      malignancies will be evaluated on a treatment schedule of five days in a row with two weeks
      off.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety,
      Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in
      patients with unresectable primary liver cancer or advanced or metastatic cancer with liver
      involvement or hematologic malignancies.  MRX34 will be administered IV twice a week as a
      single agent for 3 weeks with 1 week off (total 28 days) or daily x 5 with 2 weeks off
      (total of 21 days).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with evidence of clinical activity of MRX34</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Primary Liver Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>CLL</condition>
  <condition>CML in Accelerated or Blast Phase</condition>
  <condition>Multiple Myeloma</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>MRX34</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent MRX34</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX34</intervention_name>
    <arm_group_label>MRX34</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged ≥ 18 years

          2. Patients with histologically confirmed unresectable primary liver cancer or advanced
             metastatic cancer with liver metastasis. For the hematologic malignancy cohorts,
             patients with AML, ALL, CLL, CML in accelerated or blast phase, lymphoma, MM or MDS
             may be enrolled

          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          4. Acceptable liver function:

               -  Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); for   patients with
                  hepatocellular carcinoma only, total bilirubin ≤ 3 mg/dL (i.e. Child-Pugh Score
                  for bilirubin is no greater than 2).

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline
                  phosphatase (ALP) ≤ 5 x ULN.

          5. Acceptable renal function:

             • Serum creatinine ≤ 1.5 times the ULN, or calculated creatinine clearance ≥ 60
             mL/min/1.73 m2 for patients with creatinine levels above 1.5 times  the institutional
             normal

          6. Acceptable hematological status:

               -  Absolute Neutrophil Count (ANC) ≥ 1500 cells/mm3

               -  Platelet count ≥ 100,000 plts/mm3 (without transfusion); ≥ 75,000 plts/mm3 for
                  patients with hepatocellular carcinoma only.  For hematologic malignancy
                  patients blood counts cited above do not apply

               -  Hemoglobin ≥ 9 g/dL

               -  For the hematologic malignancy patients, blood count values cited above do not
                  apply.

          7. Prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.25 x ULN;  for
             patients with hepatocellular carcinoma only, INR &lt;1.7 or prothrombin time (PT) or &lt; 4
             seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation
             parameter); for patients with hepatocellular carcinoma only, serum albumin &gt; 2.8 g/dL
             (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic
             malignancy patients, the coagulation and albumin status cited above do not apply

          8. For patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6)
             disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no
             greater than 2 and clinically irrelevant; for the determination of the Child-Pugh
             Class.

        Exclusion Criteria:

          1. New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial
             infarction within the past 6 months, unstable and/or symptomatic arrhythmia, or
             evidence of ischemia on ECG.

          2. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic
             therapy.

          3. Pregnant or nursing women.

          4. Known infection with human immunodeficiency virus (HIV).

          5. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other
             conditions) that could compromise protocol objectives in the opinion of the
             investigator and/or the sponsor.

          6. Patients with recent history of hemorrhage and patients predisposed to hemorrhage due
             to coagulopathies or structural anomalies.

          7. Patients who require treatment with therapeutic doses of coumarin-type anticoagulants
             (maximum daily dose of 1mg allowed for port line patency permitted).

          8. Patients with cirrhosis classed as Child-Pugh B or C.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Brenner, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSCSA/CTRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN RN AOCNS</last_name>
      <phone>877-273-3713</phone>
      <email>joschaffer@shc.org</email>
    </contact>
    <investigator>
      <last_name>Jasgit Sachdev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela A McClure</last_name>
      <phone>480-301-4963</phone>
      <email>mcclure.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mitesh Borad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Avila</last_name>
      <phone>214-648-5107</phone>
      <email>adrian.avila@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammad Beg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Wilcox</last_name>
      <email>cwilcox@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Brian Herrick</last_name>
      <email>bwherrick@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uthscsa/Ctrc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
      <email>goodwine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microRNA</keyword>
  <keyword>Primary liver cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
